The nematode parasites that cause human lymphatic filariasis survive for long periods in their vascular habitats despite continual exposure to host cells. Platelets do not adhere to bloodborne microfilariae, and thrombo-occlusive phenomena are not observed in patients with circulating microfilariae. We studied the ability of microfilariae to inhibit human platelet aggregation in vitro. Brugia malayi microfilariae incubated with human platelets caused dose-dependent inhibition of agonist-induced platelet aggregation, thromboxane generation, and serotonin release. As few as one microfilaria per 104 platelets completely inhibited aggregation of platelets induced by thrombin, collagen, arachidonic acid, or ionophore A23187. Microfilariae also inhibited aggregation of platelets in platelet-rich plasma stimulated by ADP, compound U46619, or platelet-activating factor. The inhibition required intimate proximity but not direct contact between parasites and platelets, and was mediated by parasite-derived soluble factors of low (<1,000 Mj) molecular weight that were labile in aqueous media and caused an elevation of platelet cAMP. Prior treatment of microfilariae with pharmacologic inhibitors ofcyclooxygenase decreased both parasite release of prostacyclin and PGE2 and microfilarial inhibition of platelet aggregation. These results indicate that microfilariae inhibit platelet aggregation, via mechanisms that may include the elaboration of anti-aggregatory eicosanoids. (J.
Introduction
The remarkable ability offilarial parasites to persist intravascularly in the presence of host blood cells has puzzled investigators of parasitic disease (1, 2) . In lymphatic filariasis, adult worms inhabit lymphatic vessels, and release offspring microfilariae, which enter the bloodstream, where they may survive for several months or more. The lymphatic pathology in this disease is largely attributable to the adult worms. Although a brisk immune response to microfilariae occurs in the syn-drome oftropical pulmonary eosinophilia, in most patients the presence of microfilariae in the blood is not associated with specific disease manifestations; in fact, most microfilaremic patients are asymptomatic (3) . Although microfilariae may repeatedly encounter host platelets and the vascular wall, platelets do not adhere to microfilariae. Furthermore, microfilariae are not usually irreversibly trapped within small blood vessels, despite their relatively large size (-220 grm long by 10 gm diameter). Indeed, microvascular occlusion and thromboembolic phenomena characteristically do not occur in infected microfilaremic persons, even those with high-grade microfilaremias in excess of 10,000 microfilariae per milliliter of blood. The interaction between microfilariae and platelets is also of considerable importance to the parasite, because unrestricted circulation of microfilariae is critical for the transmission of filarial infections by biting mosquito vectors. The capacity of live microfilariae to affect platelet aggregation and other normal platelet responses has not been previously studied in vitro. We have previously demonstrated that microfilariae of Brugia malayi use arachidonic acid to generate prostacyclin and PGE2, which are released into the medium surrounding the parasites (4) (5) (6) . These findings suggested that microfilariae might modulate platelet responses via the release of these antiaggregatory prostanoids. We therefore examined the ability of microfilariae to inhibit platelet aggregation and assessed the potential role of parasite-derived prostanoids in this process.
Methods
Reagents. Potato apyrase (grade VIII), bovine thrombin, ADP, platelet-activating factor (1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine, PAF),' adenosine deaminase (type V), 3-isobutyl-1-methylxanthine, NV-methyl-L-arginine, Nw-nitro-L-arginine, indomethacin, and arachidonic acid (Sigma Chemical Co., St. Louis, MO) , [5, 8, 11, 14] eicosatetraynoic acid (ETYA) (Biomol Research Laboratories, Inc.; Plymouth Meeting, PA), calcium ionophore A23187 (CalbiochemBehring Corp., La Jolla, CA), collagen (Hormone-Chemie, Munich, Germany), and the PGH2 analogue U46619 (Upjohn Co., Kalamazoo, MI) were purchased from the sources indicated. Iloprost, a stable prostacyclin analogue, was a gift from Dr. E. Schillinger (Schering AG, Berlin, Germany). Compound BW755c (3-amino-143-trifluoromethylphenyl)-2-pyrazoline) was a gift from Dr. S. Moncada (Wellcome Research Laboratories, Beckenham, Kent, UK).
Isolation of microfilariae. Jirds infected intraperitoneally with B.
malayi were provided by the Filariasis Repository of the University of Georgia, Athens. Microfilariae were obtained from ketamine-anesthetized jirds by saline peritoneal lavage, and separated from jird peritoneal cells by passage over a Sephadex G-25 column as described (6) . Preparation ofplatelet suspensions. Blood from healthy donors who had not taken any medications for at least 2 wk was drawn by veni-puncture into 0.1 vol of 3.8% sodium citrate pH 6.5. After anticoagulated whole blood was centrifuged (200 g for 15 min), platelet-rich plasma was collected. For some experiments, citrated platelet-rich plasma was used directly. To prepare washed platelets, platelet-rich plasma was spun at 1,000 g for 10 min. The platelet pellet was resuspended and washed twice with HBSS containing 1 mM EGTA and 1 U/ml apyrase, and finally suspended in incubation buffer which was a modified Hepes-Tyrode's solution containing 123 mM NaCl, 8.3 mM sodium bicarbonate, 2.8 mM KCl, 0.8 mM KH2PO4, 5.6 mM dextrose, 1 mM CaC12, 0.8 mM MgCl2, and 10 mM Hepes, pH 7.4, and enumerated using a Coulter counter (model ZF; Coulter Electronics, Inc., Hialeah, FL). For experiments in which platelets were pretreated to inhibit platelet prostanoid formation, platelet-rich plasma was incubated with 1 mM aspirin at room temperature for 30 min before the wash steps. The effectiveness of aspirin treatment of platelets was verified by HPLC and RIA, which indicated > 97% reduction in platelet thromboxane generation compared to untreated platelets. For some experiments assessing platelet-derived prostanoids, washed platelets were prelabeled with [1'4Carachidonic acid (20 MM, 55 mCi/mmol; Amersham Chemical Corp., Arlington Heights, IL) in 1 ml of HepesTyrode's buffer at 37°C for 60 min, then washed three times with buffer before incubations.
Coincubation ofmicrofilariae and platelets. Washed platelets (2.5 X I08) and varying numbers ofmicrofilariae (0-2.5 X I0O) were coincubated in 1 ml of the Hepes-Tyrode's solution in polypropylene microfuge tubes (TreffAG, Degersheim, SW). To bring platelets and microfilariae into direct contact, platelets and microfilariae were first pelleted by centrifugation at 735 g for 10 min in an Eppendorf microfuge (Brinkman Instruments, Inc., Westbury, NY). Less than 1% ofthe microfilariae and < 5% of the platelets remained suspended in the medium after this centrifugation. After incubation for 60 min in a 37°C water bath, the entire pellet containing platelets and microfilariae was gently resuspended. The microfilariae were then sedimented by centrifugation at 80 g for 3 min, which allowed > 98% of the platelets to remain in suspension. For platelet aggregation assays, 0.4-ml aliquots of the platelet suspension (containing 1 X 108 platelets and < 200 microfilariae) were sampled. Platelets incubated with heat-killed microfilariae (2.5 x I05 microfilariae boiled for 5 min, then washed twice with incubation buffer) or no microfilariae, and taken through identical centrifugation steps before and after the incubation period, served as controls. For some samples, platelets and microfilariae were not pelleted at the beginning of the incubation but allowed to remain in suspension, followed by selective sedimentation ofmicrofilariae at the end of the incubation period. For incubations of microfilariae in platelet rich plasma, 2.5 x 105 microfilariae were added to 1 ml of citrated platelet-rich plasma containing -2.5-4.0 X 10" platelets/ml. The microfilariae and platelets were then pelleted and incubated, with subsequent separation of platelets and parasites, as above.
Platelet aggregation. Platelet aggregation after the addition of 0.1 U/ml ofthrombin was measured by standard turbidimetric techniques (7) , in which 0. 4 Effect ofcoincubation medium alone on platelet aggregation. Media (1 ml) was removed after a 60-min incubation of microfilariae (2.5 X 105) alone, or microfilariae and platelets (2.5 X 108), and kept at 370C for varying time periods. At different time points ranging from 30 s (the shortest feasible time) to 30 min after removal, 0.4-ml aliquots of the standing media were then added directly to pellets ofnewly washed platelets (1 X 108). Aggregation ofthese platelets suspended in incubation media was then measured as described above, and compared to that of control platelets incubated in fresh Hepes-Tyrode's solution.
Incubation ofmicrofllariae andplatelets in separate compartments. A two-compartment co-culture system (Transwell; Costar Corp., Cambridge, MA) was used for experiments requiring the physical separation of microfilariae and platelets during incubation. In this apparatus, 6.5-mm Transwell inserts with 0.4-Mm-pore size polycarbonate membrane bottoms fit inside culture wells of a 24-well polystyrene cluster plate, with a distance between the bottom of the porous membrane and the bottom of the culture well of 1 mm. Suspensions of parasites containing 1.5 X I05 microfilariae in 0.1 ml Hepes-Tyrode's solution were placed in each Transwell insert, and washed platelet suspensions containing 1.5 X 108 platelets in 0.6 ml buffer were added to the outer culture well. Incubations were carried out at 37°C for 60 min with gentle shaking (10 rpm) of the cluster plate. After incubation, 0.4-ml aliquots of the platelet suspensions in the outer wells were removed for aggregation studies. For some samples, adenosine deaminase (2 U/ml) or 3-isobutyl-1-methylxanthine (2 MM) were added to the outer well containing platelets (8) . For some experiments, the 0.4-Mm-pore size polycarbonate membranes were excised and replaced by porous cellulose membranes of exclusion sizes M, 30 ,000, 12,000-14,000, and 1,000 (Spectra/por; Spectrum Medical Industries, Inc., Los Angeles, CA). Each porous cellulose membrane was first equilibrated in HepesTyrode's incubation buffer, cut to size, and held in place on the Transwell insert with a 9-mm i.d., tight-fitting polypropylene ring fashioned from the top of a microfuge tube.
Measurement ofplatelet cyclic nucleotides. The Transwell apparatus was similarly employed in experiments to assess platelet cAMP and cGMP responses, except that numbers of microfilariae were varied, and 3-isobutyl-1-methylxanthine (2 MM) was added as a phosphodiesterase inhibitor. Resting platelet cAMP and cGMP levels were measured after 60-min incubations of washed platelets (1 X 108) with microfilariae (0-1.5 X 105). For some samples, 5 nM iloprost or 0.4% (vol/vol) nitric oxide were added in lieu of microfilariae. Nitric oxide was prepared just before use by mixing equal volumes of 300 mM sodium nitrite and 50 mM sodium acetate, pH 3.5 in deoxygenated water (9) . Ice-cold TCA (final concentration 10%) was added to 0. -ml aliquots of platelets immediately after incubations. The soluble extract was removed after centrifugation at 6,000 g for 3 min at 4°C, then washed five times with water-saturated diethyl ether to remove TCA (10) . Concentrations of platelet cAMP and cGMP were determined using RIA kits (Advanced Magnetics, Inc., Cambridge, MA) with an acetylation modification (10) .
Treatment ofmicrofilariae with pharmacologic inhibitors ofarachidonic acid metabolism. To assess the role of microfilarial prostanoid formation in parasite-platelet interactions, equal numbers of microfilariae were first incubated with or without inhibitors of prostanoid biosynthesis in 1 ml of Hepes-Tyrode's solution at 370C for 60 min, then washed three times with buffer. These agents included aspirin (100 ,M), indomethacin (100 ;M), ETYA (20 ,gM), and BW755c (100 ,MM) (6) . Microfilarial viability, assessed by motility under light microscopy, was > 97% after treatment with these agents. Platelet prostanoid biosynthesis was blocked by prior treatment with aspirin as described above. Platelets (1 X I09) were coincubated for 60 min with treated or control untreated microfilariae (1 X 106) in microfuge tubes as described above, and aliquots ofplatelets were then removed for aggregation studies. The effectiveness of pharmacologic inhibition was determined in separate experiments in which microfilariae were pretreated as above for 60 min, then incubated with ['4C]arachidonic acid (50 JM) at 370C for 60 min. Lipids in incubation media were extracted and resolved by TLC as described (5, 6) , and radioactive peaks were detected by a TLC radiation scanner (model RS; Radiomatic Instruments, Tampa, FL). Migrations of microfilarial '4C-labeled prostanoids were compared with cochromatographed 6-keto-PGFIc. and PGE2 (5), and peak areas were calculated using the manufacturer's software program.
Results
Microfilarial inhibition ofplatelet aggregation. To assess the effect of microfilariae on platelet aggregability, parasites were incubated with isolated human platelets. In this initial series of experiments, microfilariae were sedimented with the platelets to induce maximal cell contact. A 60-min incubation of normal human platelets in contact with increasing numbers of microfilariae resulted in dose-dependent inhibition of platelet aggregation stimulated by thrombin, a standard agonist for in vitro platelet aggregation (Figs. 1 and 3 A) . Tracings in Fig. 1 show that exposure ofplatelets to parasites at a ratio of 1 microfilariae per 104 platelets resulted in complete inhibition of thrombin-induced aggregation, whereas microfilariae at a greater ratio of 1 microfilaria per I03 platelets blocked agonistinduced platelet shape change (i.e., no initial decrease in amplitude of the baseline) as well as aggregation. The aggregation of washed platelets to other standard agonists was also affected: after 60 min incubation with microfilariae (microfilariae/platelet ratio 1: I03), platelet aggregation to stimulatory doses ofcollagen (2 ,ug/ml), arachidonic acid (1 AM), and ionophore A23 187 (1 IAM) was completely inhibited (not shown). Similar results were obtained using platelets treated with aspirin (not shown). Platelets were not adherent to the motile living worms when viewed under light microscopy. Platelet aggregation after incubation with heat-killed microfilariae or buffer alone was normal (Fig. 1) .
To examine the effects ofmicrofilariae on platelets in intact plasma, parasites were sedimented in platelet-rich plasma (2.5 x I05 microfilariae per ml) as above. Because thrombin is not a reliable agonist for platelets in plasma due to plasma thrombin inhibitors (7) and in vitro clot formation, several other aggregating agents were used which cause aggregation of citrated platelet rich plasma: ADP, the PGH2 analogue U466 19, and PAF. For each of these agonists, a threshold dose which resulted in primary reversible aggregation ofcontrol PRP was used (Fig. 2,  left) . The addition of microfilariae resulted in suppression of primary aggregation induced by ADP, U466 19, and PAF (Fig.  2, right) . Plasma enzymes that break down ADP reverse, but do not block, primary aggregation (7), and the addition of 2 U/ml apyrase, an exogenous ADPase, did not block ADP-induced primary aggregation of PRP (not shown). To further assess the microfilarial inhibition ofplatelet activation, agonist-induced platelet thromboxane A2 generation and serotonin release were measured. As shown in Figs. 3 B and C, increasing numbers of microfilariae caused progressive inhibition of platelet thromboxane generation and serotonin release, in concert with inhibition of aggregation.
Mechanisms ofparasite inhibition ofplatelet aggregation.
Platelet aggregability was unaffected when washed platelets and microfilariae were allowed to remain free in suspension, without close contact achieved by pelleting both platelets and microfilariae at the start ofthe incubation (percent aggregation and maximal slope of aggregation not different from control platelets, data not shown). To determine if direct physical contact was required for parasite inhibition ofplatelet aggregation, we used a dual-chamber culture apparatus in which microfilariae and washed platelets (microfilariae/platelet ratio 1: IO') were incubated in separate compartments -1 mm apart with a 0.4-,Mm-pore membrane between the two chambers. As shown in Fig. 4 , platelets incubated for 60 min in such proximity to microfilariae failed to aggregate in response to thrombin, indicating the presence of soluble mediators passing from the parasites through the permeable membrane to the platelets. Platelets incubated with heat-killed microfilariae (not shown) or no microfilariae exhibited normal aggregation (Fig. 4) . Inhibition ofplatelet aggregation was time-dependent: after 15 min incubation with microfilariae in this system, thrombin-induced platelet aggregation was inhibited 50%; after 30 min, platelet aggregation was completely inhibited; after 60 min (Fig. 4) , platelet shape change was abolished as well. Adenosine deaminase (2 U/ml) or 3-isobutyl-1-methylxanthine (2 ,M), added to the incubation to test whether adenosine contributed to inhibition, had no effect on agonist-induced platelet responses after exposure to microfilariae (not shown).
To estimate the relative size of the soluble parasite-derived mediators involved in the observed inhibition ofplatelet aggregation, dialysis membranes with exclusion sizes of 30,000, 12,000-14,000, and 1,000 Mr were substituted for the 0.4-timpore size membrane separating the platelets from microfilariae. Inhibition of platelet aggregability in the presence of microfilariae was maintained across all ofthese permeable membranes with exclusion sizes including 1,000 Mr (Fig. 4) .
To assess the stability and transferability ofthe soluble antiaggregatory property derived from microfilariae, incubation medium alone, obtained after 60 min coincubation ofparasites and platelets in microfuge tubes, was removed and added to newly isolated platelets. Fresh platelets suspended in incubation medium that was transferred almost immediately (30 s) after removal did not aggregate significantly in response to thrombin stimulation. However, most of this inhibitory effect diminished rapidly over time that the medium was allowed to stand before its addition to fresh platelets, and by 2 min after removal the medium had only a modest inhibitory effect on platelet aggregation (76% of control platelet aggregation) (Fig.  5) . Approximately 10% of the inhibitory activity of the medium was not rapidly labile within 30 min (Fig. 5) . Similar results were obtained using media from the incubation of microfilariae alone without platelets (not shown). These results indicate that the parasite-derived soluble inhibitory factors in large part were highly labile, with rapid loss of activity in aqueous media at 370C.
To determine if microfilarial inhibition of platelet responses was associated with increases in platelet cyclic nucleotide levels, platelet-associated cAMP and cGMP were measured after exposure to soluble products of microfilariae. Incubations were carried out in the dual chamber co-culture system, which also prevented any potential contribution from microfilariae to measured cyclic nucleotide levels. As shown in Fig. 6 A, resting platelet cAMP levels increased progressively in a dose-dependent manner after incubation with increasing numbers of microfilariae. Platelets incubated with the stable prostacyclin analogue iloprost at a dose of 5 nM, a concentration which inhibited platelet shape change and aggregation (not shown), served as a positive control for elevated platelet cAMP levels (Fig. 6 B) . Levels ofplatelet cGMP following exposure to microfilariae (up to I05 microfilariae/108 platelets) were not elevated compared to platelets incubated without parasites (0.8 pmol/ I0O platelets). Platelets exposed to 0.4% nitric oxide, which blocked platelet shape change and aggregation (not shown), developed 10-fold elevated cGMP levels (8.4 for the indicated time periods, then added to fresh platelets. Agonist-induced platelet aggregation is expressed as percent (means±SE ofduplicates) of maximal aggregation of control platelets incubated in buffer, and is plotted against the time period the medium was allowed to stand after removal. #mf/108 platelets Figure 6 . Microfilarial dose dependent elevation of platelet cAMP. Platelets (1.5 X 108) were incubated with microfilariae (0-1.5 X 105) for 60 min at 37°C in a Transwell co-culture system in the presence of 3-isobutyl-l-methylxanthine (2 ,gM) to block phosphodiesterase activity. A shows resting platelet cAMP levels after incubation with increasing numbers of microfilariae. B shows cAMP levels of control platelets incubated in buffer alone (PLTS) and platelets incubated with the stable prostacyclin analogue iloprost (5 nM) (PLTS + ILO). Platelet cAMP concentrations were measured by RIA after extraction, and represent the means±SEM of four experiments.
Role ofmicrofilarialprostanoid release in inhibition ofplatelet aggregation. To determine if microfilarial prostanoid release contributed to parasite inhibition of platelet aggregation, microfilariae were treated with inhibitors of enzymatic prostanoid formation before incubation with platelets. Indomethacin, ETYA, and compound BW755c have been previously demonstrated to block microfilarial prostanoid formation (6) . Pretreatment ofmicrofilariae with either aspirin or these agents blocked the capacity ofthe parasites to inhibit platelet aggregation (Fig. 7) ; i.e., platelet aggregation after incubation with treated microfilariae approached that of control platelets incubated without parasites. The effectiveness of treatment with these agents was determined by prelabeling similar numbers of microfilariae with ['4C]arachidonic acid (50 pM) and thinlayer chromatography analysis of released prostanoids from treated or untreated microfilariae. Microfilarial '4C-labeled prostanoid formation was significantly reduced by all of these agents, ranging from 79% inhibition by aspirin to 87% inhibition by ETYA, in comparison to untreated microfilariae.
Discussion
This study was designed to examine the effect of intact living microfilariae on the function ofhuman platelets, and the possible role ofparasite-derived prostanoids in mediating this effect. Our results indicate that microfilariae of B. malayi inhibit the aggregation of human platelets in a potent manner which is dependent, in part, on the elaboration ofanti-aggregatory eicosanoids by the parasites.
Microfilariae sedimented with platelets exerted a striking and potent effect on platelet aggregability. Under these experimental conditions, a single microfilaria per 104 platelets was sufficient to completely suppress thrombin-induced platelet aggregation, while one microfilaria per I03 platelets suppressed platelet shape change as well. Conventional quantitative indicators of platelet activation, including platelet thromboxane generation and serotonin release, were likewise inhibited by microfilariae in a potent dose-dependent fashion. These parasite effects were not due to neutralization ofthe thrombin agonist itself(e.g., by secretion in vitro ofa hirudin-like substance) since the aggregation of isolated platelets was similarly suppressed to diverse agonists including collagen, arachidonic acid, and calcium ionophore. Furthermore, these anti-platelet effects were also observed using platelet-rich plasma instead of washed platelets, wherein microfilariae suppressed aggregation induced by ADP, the PGH2 analogue U466 19, or platelet activating factor. Thus, although plasma might be expected to contain host factors which would counteract parasite metabolism, the suppressive effect of parasites was retained in this more physiological milieu. Because a wide variety ofagonists (which act by different mechanisms) were used, the inhibitory effect of microfilariae appeared to be predominantly on intrinsic platelet responsiveness, rather than via agonist-specific effects. Living microfilariae were required for the inhibition of platelet aggregation, which was unaffected following contact with heat-killed microfilariae. Although platelets in direct contact with microfilariae were inhibited, platelets -1 mm proximate to microfilariae but separated by a porous membrane were also inhibited. Thus, the capacity of microfilariae to inhibit platelet aggregation under these conditions could be accounted for by the metabolic release ofsoluble parasite-derived factors of low molecular weight (< 1,000 Mr). Supernatant fluid (taken after 60 min incubation when inhibition ofplatelet aggregation and shape change were maximal) contained inhibitory activity if assayed immediately, but most activity was lost within minutes, indicating that the parasite-derived paracrine factors were in large part labile and did not accumulate in aqueous medium at 37°C. This lability may have accounted for the observation that only microfilariae in close proximity to platelets and not those in free suspension inhibited platelet aggregability. The soluble microfilarial-derived products exhibited a dose-dependent capacity to elevate platelet cAMP (but not cGMP), which with large numbers ofparasites approached levels of platelet cAMP induced by iloprost, an approximately equipotent analogue of natural prostacyclin (13) . These results indicate that microfilariae may inhibit platelet aggregation by releasing factors which cause a rise in platelet cAMP.
Several naturally occurring low-molecular weight compounds are known to inhibit platelet aggregation by receptor or non-receptor-mediated stimulation of platelet adenylate cyclase. These agents include the f3-adrenergic catecholamines, adenosine, forskolin, and the anti-aggregatory prostanoids, particularly prostacyclin (14) . However, except for prostacyclin, all of these compounds are relatively stable and accumulate in aqueous media, and thus are unlikely to account for the observed potent but labile parasite-derived effects on platelets. In particular, adenosine, though widely distributed in nature, is not a potent inhibitor of aggregation, and its effects can be blocked by methylxanthines, which act as adenosine receptor antagonists (15) . In our studies, the addition of either 3-isobutyl-l-methylxanthine or adenosine deaminase (which would destroy soluble adenosine) did not affect the capacity of microfilariae to suppress platelet responses, thus effectively excluding a role for adenosine in these observations. Another class of unstable natural compounds which can inhibit platelet function are organic nitrates, including nitric oxide (endotheliumdependent relaxing factor) or nitrosothiol compounds, which act by stimulating soluble guanylate cyclase (16) . However, in our experiments, platelet levels of cGMP were not increased after exposure to the parasites, and pretreatment of the parasites with competitive inhibitors of nitric oxide formation did not affect the capacity of microfilariae to inhibit platelet aggregation.
The anti-aggregatory prostanoids are well-described and important physiological factors which inhibit platelet aggregation. These include prostacyclin, PGD2, and PGE2 in decreasing order of potency (17) . We have previously demonstrated that microfilariae of B. malayi elaborate prostacyclin and PGE2 (but not the pro-aggregatory compound thromboxane A2) from endogenous as well as exogenous arachidonic acid (6) . Release of prostanoids into the microenvironment surrounding B. malayi and Wuchereria bancrofti microfilariae can also be demonstrated by immunocytochemistry (17a). To examine a possible association between parasite-derived prostanoids and the observed effects on platelets, microfilariae were first treated with either (a) aspirin, which irreversibly inactivates cyclooxygenase; (b) indomethacin, an inhibitor of prostanoid formation whose mechanism is poorly understood; (c) BW755c, a pyrazoline anti-oxidant inhibitor offatty acid oxygenation; or (d) ETYA, a nonmetabolizable fatty acid analogue that competitively inhibits fatty acid metabolism. The effectiveness of these agents in blocking parasite prostanoid formation was verified biochemically using radiolabeled arachidonic acid. Treatment of similar numbers of microfilariae with aspirin, indomethacin, BW755c, or ETYA resulted in a loss of the capacity of these parasites to inhibit platelet aggregation when compared to normal, untreated microfilariae. These findings indicate that microfilarial elaboration of prostanoids contributes to the inhibition of platelet aggregation.
Our results also suggest that prostacyclin is the predominant parasite-derived prostanoid involved in inhibition ofplatelet aggregation. Prostacyclin, the most potent known natural inhibitor of platelet aggregation (14, 15, 18) , is the most abun-dant prostanoid formed by microfilariae (6) . Furthermore, it is the only anti-aggregatory prostanoid which is rapidly and spontaneously hydrolyzed within minutes (18) in aqueous media to an inactive metabolite, namely 6-keto-PGF,,. Parasite-derived prostacyclin could thus represent the bulk of the inhibitory activity, which degraded rapidly in transferred media. Because PGE2 is a relatively weak inhibitor of platelet aggregation, it probably did not account for the small residual inhibitory activity which did not degrade rapidly in media. Transcellular metabolism of arachidonate may occur between different cell types; in particular, both endothelial cells and lymphocytes have been shown to synthesize prostacyclin from platelet-derived prostaglandin endoperoxides (19, 20) . Thus, platelets could have donated prostaglandin endoperoxides to microfilariae towards the generation of prostacyclin. However, this is unlikely because similar platelet inhibitory responses were obtained using platelets treated with aspirin to block prostaglandin endoperoxide formation or using incubation media from parasites alone; furthermore, no radiolabeled prostacyclin was detected after the incubation ofmicrofilariae with platelets prelabeled with ['4C]arachidonic acid (not shown). Among the eicosanoids formed by lipoxygenase enzymes, 1 3-hydroxyoctadecadienoic acid (derived from linoleic acid), has been postulated to inhibit platelet adhesion (21) . However, in independent experiments, we were unable to detect the formation of radiolabeled 13-hydroxyoctadecadienoic acid from ['4C]linoleic acid by B. malayi microfilariae using reverse HPLC for lipoxygenase metabolites (not shown).
Proteins or other stable factors may have contributed to the residual inhibitory activity against platelets that did not degrade rapidly in media. In this regard, Foster et al. recently showed that water-soluble extracts ofB. malayi microfilariae at a concentration of 0.1 mg/ml inhibited platelet aggregation induced by collagen and ADP, and that induced by arachidonic acid at a concentration of 0.6 mg/ml of extract (22) . Microfilarial extracts as well as parasite culture medium also inhibited activation of factor XII (Hageman factor) in their study. Although the water-soluble extracts were not further characterized, these findings suggested the action of stable protein-like factors. A number of secreted parasite proteins are in fact enzymes, whose functional significance in most cases has yet to be determined (23) . In terms of anti-hemostatic mechanisms, such products might not necessarily affect platelets directly but instead inhibit platelet aggregation by degrading proaggregatory molecules such as ADP (i.e., an apyrase-like activity), thrombin (a hirudin-like activity) or PAF. Indeed, secreted proteins from the rat nematode Nippostrongylus brasiliensis have recently been demonstrated to specifically inhibit PAFinduced platelet aggregation via enzymatic cleavage of PAF (24) . In contrast, our results indicate a major direct effect of parasite-derived mediators on platelet responsiveness, and we did not, under the experimental conditions ofthis study, detect an inhibition of either thrombin, ADP, or PAF per se used as agonists.
Our results demonstrate that a helminthic parasite can actively inhibit platelet aggregation, and suggest that parasite-derived eicosanoids may down-regulate host cellular responses. Although the present study did not address the effects ofmicrofilariae on the vascular wall, prostacyclin and PGE2 are also potent vasodilators (25) . The parasite release of these anti-aggregatory and vasodilatory prostanoids might therefore permit microfilariae to pass through capillary vessels. In the case of these bloodborne worms, such unrestricted circulation through the bloodstream is essential to sustain their parasitic life cycle. Microfilariae must be available for ingestion in the bloodmeal of vector mosquitos to reach subsequent developmental stages within mosquitos and perpetuate transmission of this parasitic infection. Because prostanoids are not stable circulating hormones (26, 27) , parasite-derived prostanoids would be unlikely to exert deleterious systemic effects on the host. Indeed, bleeding phenomena due to abnormal platelet function or hemostasis is not a recognized clinical problem in microfilaremic patients. Our findings may also be germane to the intravascular stages of other metazoan parasites, including microfilariae of Wuchereria bancrofti, Onchocerca volvulus, Loa loa, and Mansonella perstans, and adult stages of the trematode Schistosoma. Platelets, in concert with specific antibodies, have been shown to have a cytotoxic effect in vitro against certain helminthic parasites (28) (29) (30) 
